SISCAPA Assay Technologies
SISCAPA Assay Technologies specializes in developing, performing, and supporting definitive immunoaffinity-MS assays for protein drugs, targets, and biomarkers. Founded in 2011, the company has developed hundreds of assays used in clinical trials, diagnostics, and research. Their technology combines mass spectrometry and specific antibody recognition to solve challenging protein measurement problems encountered in drug development, clinical trials, and diagnostics. SISCAPA assays offer high precision, sensitivity, and specificity, enabling accurate quantification of therapeutic drugs, drug targets, biomarkers, and proteins involved in gene therapy, inflammation, and other health monitoring applications. The company’s automated workflows and multiplexing capabilities facilitate high-throughput, interference-free protein analysis across various sample types, including serum, plasma, tissue, dried blood spots, and more. SISCAPA’s solutions support longitudinal health studies, infectious disease diagnostics, and the development of personalized medicine tools.
Industries
Nr. of Employees
small (1-50)
SISCAPA Assay Technologies
Patents
Products
Longitudinal dried blood-spot measurement platform
A platform for high-frequency longitudinal measurement of protein biomarkers from dried blood spots, designed to support repeated home sampling and longitudinal clinical studies with standardized assays and data workflows.
Compact microsampling and contextual data capture system
A user-oriented DBS sampling device and accompanying workflow for capturing contextual information (e.g., wearable sensor data) to support at-home sample collection and longitudinal studies.
Longitudinal dried blood-spot measurement platform
A platform for high-frequency longitudinal measurement of protein biomarkers from dried blood spots, designed to support repeated home sampling and longitudinal clinical studies with standardized assays and data workflows.
Compact microsampling and contextual data capture system
A user-oriented DBS sampling device and accompanying workflow for capturing contextual information (e.g., wearable sensor data) to support at-home sample collection and longitudinal studies.
Services
End-to-end development of targeted peptide assays including proteotypic peptide selection, anti-peptide reagent generation and supply, automated assay optimization, and qualification for deployment in serum, DBS, tissue and other matrices.
Non-GLP sample analysis, custom and catalog multiplex panels, and longitudinal dried blood spot study analysis for research and clinical trial support.
End-to-end development of targeted peptide assays including proteotypic peptide selection, anti-peptide reagent generation and supply, automated assay optimization, and qualification for deployment in serum, DBS, tissue and other matrices.
Non-GLP sample analysis, custom and catalog multiplex panels, and longitudinal dried blood spot study analysis for research and clinical trial support.
Expertise Areas
- Immuno-affinity mass spectrometry for targeted proteomics
- Assay development for protein drugs, drug targets and biomarkers
- Longitudinal biomarker monitoring using dried blood spots
- Multiplexed proteomic panel design and implementation
Key Technologies
- Peptide immuno-affinity enrichment (anti-peptide antibodies)
- Isotope-dilution mass spectrometry with labeled peptide standards
- Multiple-reaction monitoring (MRM) on triple-quadrupole MS
- MALDI-TOF, QTOF and Orbitrap mass spectrometry platforms
News & Updates
High resolution two-dimensional electrophoresis of human plasma proteins.
A two-dimensional gel database of human plasma proteins.
Multi-component immunoaffinity subtraction chromatography: an innovative step towards a comprehensive survey of the human plasma proteome.
The Human Plasma Proteome: A Non-Redundant List Developed by Combination of Four Separate Sources.
Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins.
The Clinical Plasma Proteome: A Survey of Clinical Assays for Proteins in Plasma and Serum.
High resolution two-dimensional electrophoresis of human plasma proteins.
A two-dimensional gel database of human plasma proteins.
Multi-component immunoaffinity subtraction chromatography: an innovative step towards a comprehensive survey of the human plasma proteome.
The Human Plasma Proteome: A Non-Redundant List Developed by Combination of Four Separate Sources.
Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins.
The Clinical Plasma Proteome: A Survey of Clinical Assays for Proteins in Plasma and Serum.